ASCO 2019 | Characterizing bridging strategies for CAR T-cell therapy

Name: Characterizing bridging strategies for CAR T-cell therapy
Uploaded: 2019-06-01T00:00:00.000Z
Duration: 59 s
Description: Karlo Perica, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, explains the rationale behind a retrospective review of adult patients with R/R acute lymphoblastic leukemia (ALL) treated with 19-28z CAR-T therapy seeking to characterize bridging strategies. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Karlo Perica • 1 Jun 2019

ASCO 2019

Acute Lymphoblastic Leukemia

Karlo Perica, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, explains the rationale behind a retrospective review of adult patients with R/R acute lymphoblastic leukemia (ALL) treated with 19-28z CAR-T therapy seeking to characterize bridging strategies. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.